Case Report: Long-lasting adrenal insufficiency following successful osilodrostat therapy with subsequent recurrence of Cushing’s syndrome
- 1Chair and Department of Endocrinology, Jagiellonian University Medical College
Abstract
Osilodrostat is an effective steroidogenesis inhibitor used in the treatment of Cushing’s syndrome (CS). One of the clinically significant adverse events associated with this therapy is adrenal insufficiency (AI). Here, we report a patient with CS who developed delayed-onset AI during osilodrostat therapy, that persisted for four years despite drug discontinuation and was followed by recurrence of hypercortisolism. A 52-year-old female was admitted with suspicion of CS. Diagnostic evaluation suggested pituitary CS. Ketoconazole was initiated as a preoperative treatment, however, transsphenoidal surgery (TSS) proved non-radical. The patient declined reoperation, and was therefore treated with metyrapone within a clinical trial (NCT02297945), followed by transition to osilodrostat after the trial’s completion. After two years of successful treatment with a stable dose of osilodrostat the patient developed AI. The drug was discontinued, however AI persisted for the next 4 years. The symptoms suggestive of CS recurred, which led to another TSS, that resulted in remission. After 10 months of remission, hypercortisolism recurred again. This case highlights the need for careful long-term monitoring in patients receiving adrenostatic therapy. It is particularly notable for delayed onset of AI, despite long-term treatment with a stable, relatively low dose of osilodrostat. The prolonged persistence of AI and the subsequent late recurrence of hypercortisolism further distinguish this case from previously reported cases. Overall, this case underscores the need for continued clinical vigilance during long-term osilodrostat treatment.
Related
- Steroid Withdrawal Syndrome and Adrenal Insufficiency Following Unsupervised Steroid Use: A Case Report.
- Recurrence of Helicobacter Pylori after Successful Eradication in Northwestern China: Rates, Risk Factors, and Resistance Profiles of Recurrence Isolates.
- Serial 4-Dimensional Flow Cardiac Magnetic Resonance Imaging Visualizes Incremental Hemodynamic Improvement Following Alcohol Septal Ablation and Subsequent Mavacamten Therapy
- Successful Bailout Retrieval of an Active‐Fixation Atrial Leadless Pacemaker Following Suspected Tissue Entrapment During Repositioning
- Case Report: Successful needle revision of an encapsulated bleb following PAUL glaucoma Implant surgery in a pediatric patient
BibTeX
@article{suchy2026case,
title = {{Case Report: Long-lasting adrenal insufficiency following successful osilodrostat therapy with subsequent recurrence of Cushing’s syndrome}},
author = {Wiktoria Suchy and Ewelina Rzepka and Mari Minasyan and Aleksandra Gamrat-Żmuda and Alicja Hubalewska-Dydejczyk and Aleksandra Gilis-Januszewska},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1962865},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1962865/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case Report: Long-lasting adrenal insufficiency following successful osilodrostat therapy with subsequent recurrence of Cushing’s syndrome
AU - Wiktoria Suchy
AU - Ewelina Rzepka
AU - Mari Minasyan
AU - Aleksandra Gamrat-Żmuda
AU - Alicja Hubalewska-Dydejczyk
AU - Aleksandra Gilis-Januszewska
PY - 2026
DA - 2026/10/14
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1962865
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1962865/full
AB - Osilodrostat is an effective steroidogenesis inhibitor used in the treatment of Cushing’s syndrome (CS). One of the clinically significant adverse events associated with this therapy is adrenal insufficiency (AI). Here, we report a patient with CS who developed delayed-onset AI during osilodrostat therapy, that persisted for four years despite drug discontinuation and was followed by recurrence of hypercortisolism. A 52-year-old female was admitted with suspicion of CS. Diagnostic evaluation suggested pituitary CS. Ketoconazole was initiated as a preoperative treatment, however, transsphenoidal surgery (TSS) proved non-radical. The patient declined reoperation, and was therefore treated with metyrapone within a clinical trial (NCT02297945), followed by transition to osilodrostat after the trial’s completion. After two years of successful treatment with a stable dose of osilodrostat the patient developed AI. The drug was discontinued, however AI persisted for the next 4 years. The symptoms suggestive of CS recurred, which led to another TSS, that resulted in remission. After 10 months of remission, hypercortisolism recurred again. This case highlights the need for careful long-term monitoring in patients receiving adrenostatic therapy. It is particularly notable for delayed onset of AI, despite long-term treatment with a stable, relatively low dose of osilodrostat. The prolonged persistence of AI and the subsequent late recurrence of hypercortisolism further distinguish this case from previously reported cases. Overall, this case underscores the need for continued clinical vigilance during long-term osilodrostat treatment.
SN - 1664-2392
ER -